Triple
T6006170
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Sanofi |
E133715
|
entity |
| Predicate | formerlyKnownAs |
P65
|
FINISHED |
| Object | Sanofi-Aventis |
E133715
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Sanofi-Aventis | Statement: [Sanofi, formerlyKnownAs, Sanofi-Aventis]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Sanofi-Aventis Context triple: [Sanofi, formerlyKnownAs, Sanofi-Aventis]
-
A.
Sanofi
chosen
Sanofi is a major French multinational pharmaceutical company known for developing prescription medicines, vaccines, and consumer healthcare products worldwide.
-
B.
Roche
Roche is a common surname of French origin borne by various notable individuals across fields such as architecture, politics, and the arts.
-
C.
Roche
Roche is a major Swiss multinational healthcare company and one of the world’s leading pharmaceutical and diagnostics firms.
-
D.
Novartis
Novartis is a global Swiss-based pharmaceutical company known for developing innovative medicines across a wide range of therapeutic areas.
-
E.
Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company known for developing and manufacturing innovative medicines in areas such as oncology, immunology, and cardiovascular disease.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c00872444c8190bfaf1739dcec765c |
completed | March 22, 2026, 3:19 p.m. |
| NER | Named-entity recognition | batch_69c04f128354819088971ee398cbda77 |
completed | March 22, 2026, 8:20 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c11ce452748190b8b798a5cc2922f2 |
completed | March 23, 2026, 10:58 a.m. |
Created at: March 22, 2026, 4:06 p.m.